Henry, David H.

Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study

Scagliotti, G. V., Hirsh, V., Siena, S., Henry, D. H., Woll, P. J., Manegold, C., Solal-Celigny, P., Rodriguez, G., Krzakowski, M., Mehta, N. D., et al. (2012) · Journal of Thoracic Oncology

Bone health and treatmentsLung Cancer Treatments and Mutations

Cited by 335

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., et al. (2014) · Supportive Care in Cancer

Bone health and treatmentsBone health and osteoporosis research

Cited by 183

High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?

Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008) · Journal of the American Society of Nephrology

Iron Metabolism and DisordersPharmacovigilance and Adverse Drug Reactions

Cited by 56